Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis

CONCLUSIONS: Use of RTS,S results in reductions in malaria cases and deaths even when layered upon existing interventions. When comparing relative cost-effectiveness, scale up of ITNs, introduction of SMC, and switching to new technology nets should be prioritized in eligible settings.PMID:37080831 | DOI:10.1016/j.vaccine.2023.04.011

Source: Vaccine - April 18, 2023 Category: Allergy & Immunology Authors: Hillary M Topazian Nora Schmit Ines Gerard-Ursin Giovanni D Charles Hayley Thompson Azra C Ghani Peter Winskill Source Type: research